Nama's AI scorecard currently rates CareDx Buy (5.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CDNA's P/E ratio?

CareDx trades at a trailing price-to-earnings ratio of 51.4.

When does CDNA report earnings?

CareDx's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.36.

What is the CDNA price target?

The median analyst price target from 6 analysts is $91.00, with a range of $90.00 – $100.00.

Is CDNA Shariah compliant?

Nama's AAOIFI-style screen reads CareDx as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

CareDx (CDNA)

Healthcare · Diagnostics Research · NASDAQ

CareDx (CDNA) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $4.13B, a trailing price-to-earnings ratio of 51.4 and a free-cash-flow yield of 0.8%. Over the most recent reported fiscal year, revenue grew 13.8% and free cash flow per share grew 19.3%. Nama's AI scorecard rates it Buy, 5.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 5.8/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +320.0% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-13.6%

How far the last close sits under the highest price of the past five years.

Market cap	$4.13B
Trailing P/E	51.4
Price / book	9.5
Price / sales	8.3
FCF yield	0.8%
Dividend yield	—
Gross margin	70.6%
Operating margin	-0.9%
Net margin	24.2%
Revenue growth (YoY)	+13.8%
Revenue growth (3-yr annual)	+5.7%
EPS growth (YoY)	+11.1%
FCF/share growth (YoY)	+19.3%
Beta	2.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

CDNA earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.36). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.70	$0.26	+169.2%	$139.36M
Q2 2026	Jul 30, 2026	$0.37	$0.23	+60.9%	$131.95M
Q1 2026	Apr 28, 2026	$0.34	$0.13	+161.5%	$117.70M
Q4 2025	Feb 24, 2026	$0.12	$0.23	-47.8%	$108.39M

CDNA analyst price target

Median target $91.00 from 6 analysts, ranging $90.00 – $100.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live CDNA data on Nama Insights →

CDNA FAQ

Is CDNA a buy?: Nama's AI scorecard currently rates CareDx Buy (5.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CDNA's P/E ratio?: CareDx trades at a trailing price-to-earnings ratio of 51.4.
When does CDNA report earnings?: CareDx's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.36.
What is the CDNA price target?: The median analyst price target from 6 analysts is $91.00, with a range of $90.00 – $100.00.
Is CDNA Shariah compliant?: Nama's AAOIFI-style screen reads CareDx as Not Shariah Compliant. At least one of the three ratios or the industry test failed.